AGM

I'm planning to attend the AGM. I'm hopeful, but doubtful, some clear guidance will be given re:
(a) what conclusions yet arrived at re Ph 3 results; especially any significant differences between various trial sites, sub-classes of patients on trial (especially prior treatments, KRAS issues, etc)
(b) Thinking re ongoing Ph 2 trials
(c) Overall thoughts re overall future prospects/value of HyAct platform
(d) Fonda - future prospects & plans
(e) VAST - including status of Astra Zeneca deal
(f) budget cutting plans
(e) overall strategy to restore shareholder value

I hope I'm wrong, but recent communications I've had suggested they were going to take 6-8 weeks to come up with real answers to above questions.
The only very small bit of 'solace' I've had in past week or so is that the Ph 3 result has apparently been a huge unexpected shock to all inside ACL